CYTK
$7.26
Cytokinetics
($.52)
(6.68%)
CYTK
Earnings Whisper ®
N/A
3rd Quarter September 2018
Consensus:  ($0.53)
Revenue:  $2.23 Mil
Thursday
Nov 1
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CYTK reports earnings?
Beat
Meet
Miss

Where is CYTK's stock price going from here?
Up
Flat
Down
Stock chart of CYTK
Analysts
Summary of analysts' recommendations for CYTK
Score
Grade
Pivots
Resistance
$8.74
$8.43
$7.84

$7.53

Support
$6.94
$6.63
$6.04
Tweet
Growth
Description
CYTOKINETCS is a different kind of company. It is increasingly unusual that an emerging growth biotechnology company would be dedicated to the discovery, development and commercialization of therapeutics. Similarly, it is more and more uncommon for a biopharmaceutical company to tackle the pursuit of new treatments for multiple disease areas, including cancer and cardiovascular diseases. However, the most important distinguishing feature of Cytokinetics is instead found in our commitment to innovation that has translated our focus on the cytoskeleton into a Research and Development pipeline of multiple, first-in-class compounds. All of the programs we are pursuing offer entirely novel therapeutic approaches to severe unmet clinical needs. The reason is simple. Innovative therapeutics are much more likely to bring substantial benefits to patients.
Peers
CelgeneRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalEndo International plcJohnson & JohnsonUltragenyx PharmaceuticalBristol-Myers SquibbEli LillyMylan